Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The Company's powerful research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allow Affimed to identify antibodies against even the most difficult of targets. Affimed's proprietary antibody formats include 'TandAbs™', unique tetravalent antibodies that are particularly well suited to targeting tumor cells. Affimed's two most advanced therapeutic programs, in late preclinical development, comprise TandAbs™ leads in Non-Hodgkin's Lymphoma and Hodgkin's Disease. Affimed is based in Heidelberg, Germany.

Speaker Profile

Dr. Rolf H. Günther, Chief Executive Officer

Dr. Günther is Chief Executive Officer of Affimed.
Prior to joining Affimed he held positions at Aventis Behring as Vice President of Global Clinical Research and Development. Following positions included head of world-wide R&D and Vice President & General Manager of the Business Unit Critical Care.
Prior to this Dr. Günther held positions in sales & marketing, R&D and strategic planning at Aventis, Aventis Behring and their predecessor companies.

Education: MD from Medical School of University of Mainz, Germany, PhD in Physical Chemistry from the University of Mainz, Germany, Wharton Business School, Philadelphia, US.